Literature DB >> 24898388

Genotype CC of rs12979860 is providing protection against infection rather than assisting in treatment response for HCV genotype 3a infection.

A H Hashmi1, N Ahmad1, S Riaz1, L Ali1, S Siddiqi1, K M Khan2, A R Shakoori3, A Mansoor1.   

Abstract

Recent discovery of single-nucleotide polymorphisms located in the upstream region of interleukin-28B (IL28B) has shown association with interferon (IFN) treatment response especially in hepatitis C virus (HCV) genotype 1-infected patients. Pakistan, being the country with second highest prevalence of HCV with predominantly 3a genotype infection, bears a significant disease burden. The present study was conducted to evaluate the effect of rs12979860 genotypes on treatment response in HCV-3a-infected patients. This study shows that the CC genotype is providing protection against infection to HCV. But once infected, the CC genotype patients show viral persistence following IFN therapy. The TT genotype is assisting the 3a patients in viral clearance after IFN treatment. To our knowledge, this is the first study showing rs12979860 genotype association with IFN response in Pakistani HCV-3a-infected patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24898388     DOI: 10.1038/gene.2014.31

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  23 in total

1.  Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial.

Authors:  Savino Bruno; Calogero Cammà; Vito Di Marco; Mariagrazia Rumi; Maria Vinci; Mario Camozzi; Chiara Rebucci; Danilo Di Bona; Massimo Colombo; Antonio Craxì; Mario U Mondelli; Giovanbattista Pinzello
Journal:  J Hepatol       Date:  2004-09       Impact factor: 25.083

2.  Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

Authors:  Albert Friedrich Stättermayer; Rudolf Stauber; Harald Hofer; Karoline Rutter; Sandra Beinhardt; Thomas Matthias Scherzer; Kerstin Zinober; Christian Datz; Andreas Maieron; Emina Dulic-Lakovic; Harald H Kessler; Petra Steindl-Munda; Michael Strasser; Christoph Krall; Peter Ferenci
Journal:  Clin Gastroenterol Hepatol       Date:  2010-08-20       Impact factor: 11.382

Review 3.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.

Authors:  J M Micallef; J M Kaldor; G J Dore
Journal:  J Viral Hepat       Date:  2006-01       Impact factor: 3.728

4.  A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.

Authors:  Philippe Halfon; Marc Bourliere; Denis Ouzan; Yaakov Maor; Christophe Renou; Claire Wartelle; Guillaume Pénaranda; Albert Tran; Danielle Botta; Valérie Oules; Paul Castellani; Isabelle Portal; Laurent Argiro; Alain Dessein
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-10       Impact factor: 2.566

5.  Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.

Authors:  Pablo Barreiro; Juan Antonio Pineda; Norma Rallón; Susanna Naggie; Luz Martín-Carbonero; Karin Neukam; Antonio Rivero; José Miguel Benito; Antonio Caruz; Eugenia Vispo; Angela Camacho; José Medrano; John McHutchison; Vincent Soriano
Journal:  J Infect Dis       Date:  2011-06-01       Impact factor: 5.226

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

Authors:  Juan A Pineda; Antonio Caruz; Antonio Rivero; Karin Neukam; Irene Salas; Angela Camacho; José C Palomares; José A Mira; Antonio Martínez; Carmen Roldán; Julián de la Torre; Juan Macías
Journal:  Clin Infect Dis       Date:  2010-10-01       Impact factor: 9.079

8.  Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads.

Authors:  Hitomi Sezaki; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2008-10-28       Impact factor: 3.199

9.  IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection.

Authors:  Ayman A Abdo; Mohammed N Al-Ahdal; Saira S Khalid; Ahmed Helmy; Faisal M Sanai; Khalid Alswat; Waleed Al-Hamoudi; Safiyya M Ali; Hamad I Al-Ashgar; Abdallah Al-Mdani; Ali Albenmousa; Faleh Z Al Faleh; Mashael Al-Anazi; Nisreen Khalaf; Ahmed Al-Qahtani
Journal:  Hepatol Int       Date:  2013-02-08       Impact factor: 6.047

Review 10.  Hepatitis C virus genotypes in Pakistan: a systemic review.

Authors:  Sobia Attaullah; Sanaullah Khan; Ijaz Ali
Journal:  Virol J       Date:  2011-09-08       Impact factor: 4.099

View more
  2 in total

1.  Predictive potential of IL-28B genetic testing for interferon based hepatitis C virus therapy in Pakistan: Current scenario and future perspective.

Authors:  Muhammad Sohail Afzal
Journal:  World J Hepatol       Date:  2016-09-18

Review 2.  A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges.

Authors:  Muhammad Ali; Samia Afzal; Asad Zia; Ahmed Hassan; Ali Talha Khalil; Muhammad Ovais; Zabta Khan Shinwari; Muhammad Idrees
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.